Skip to content
December 09, 2024

Investment information for the new generation

Search

April 21, 2021

Cybin (CYBN.NE) announced that they have successfully demonstrated Proof of Concept for their deuterated tryptamine programs, CYB003 and CYB004. The Proof of Concept revolves around the duration of psilocybin….
Dead on arrival The European super league died before it even got started, putting 12 of Europe’s top teams in an incredibly awkward situation. All six of England’s breakaway…
Isracann Biosciences (IPOT.C) received a foreign owner cannabis license from the Israeli Minister of Health today, according to a press release. Getting this license concludes Isracann’s regulatory compliance requirements…
Aion Therapeutics’ (AION.C) proprietary and patented combinatorial mushroom preparations, Aion F7 and Aion F8, have shown high efficacy in killing HER2+ breast cancer cells, ER+/PR+ breast cancer cells, and…
After forming a Double Bottom at key support on March 8th and March 31st, Gold mounted a successful assault on the $1750 line, a bulwark that has kept prices in…
Dogecoin was up nearly 8,000% on the year when it hit all time highs around $0.44. The meme coin was up 400% in the 7 days leading to April…
Mind Cure (MCUR.C) has partnered with Lucid Inc. to design custom psychedelic music experiences for the Company’s iSTRYM technology. “We are building first-of-its-kind functionality by pairing AI-driven music scapes…
Reliq Health Technologies (RHT.V) has signed contracts with two U.S. nephrology practices to use the Company’s proprietary iUGO Care Platform to monitor chronic kidney disease (CKD) patients. “It is…
Core One Labs’ (COOL.C) wholly-owned subsidiary Vocan Biotechnologies has initiated the design and engineering of a proprietary enzymatic production system for API-grade N,N-dimethyltryptamine, commonly known as DMT. DMT, also…
Street cred MindMed (MMED.NEO) announced last fall it was applying to be listed on the Nasdaq Exchange. MindMed would be the first Canadian psychedelics company listed on a major…